Brief: Heidelberg Pharma Participates In Franco-German Joint Venture

Heidelberg Pharma AG

20/11/2019 14:24

Nov 20 (Reuters) - HEIDELBERG PHARMA AG  WL6G.DE :
    * PARTICIPATES IN FRANCO-GERMAN JOINT VENTURE EMERGENCE
THERAPEUTICS AND SIGNS COLLABORATION AND LICENSE AGREEMENT
    * JOINT RESEARCH INTO DEVELOPMENT CANDIDATES PLANNED
    * HEIDELBERG PHARMA CONTRIBUTING ANTIBODY TARGETED AMANITIN
CONJUGATE TECHNOLOGY FOR EMERGENCE THERAPEUTICS ANTIBODY TARGET
    * WILL PARTICIPATE IN JOINT VENTURE EMERGENCE THERAPEUTICS
AG
TOGETHER WITH FRENCH AND GERMAN INVESTORS, LED BY LEAD INVESTOR
KURMA PARTNERS
    * IS INVOLVED IN START-UP PHASE BOTH AS PARTNER AND VIA
CONVERTIBLE BONDS AND CAN INCREASE ITS STAKE TO AROUND 20%
DURING SEED ROUND
    * WILL CONTRIBUTE ITS TOXIN LINKER TECHNOLOGY FOR ANTIBODY
TARGETED AMANITIN CONJUGATES (ATACS) AS PART OF A LICENSE AND
DEVELOPMENT AGREEMENT
    * WILL ALSO MANUFACTURE EXPERIMENTAL ATAC MOLECULES AND
CONTRIBUTE
TO RESEARCH ACTIVITIES
    * PARTNERS WILL WORK TOGETHER TO MANUFACTURE NOVEL ATACS AND
SELECT A CANDIDATE FOR FURTHER DEVELOPMENT
    * AS A SHAREHOLDER, HEIDELBERG PHARMA WILL ALSO PARTICIPATE
IN
POTENTIAL INCREASE IN VALUE OF JOINT VENTURE
    * LICENSE AGREEMENT PROVIDES FOR REGULATORY AND COMMERCIAL
MILESTONE PAYMENTS AND ROYALTIES

Source text for Eikon:  ID:nEQ7B5RtPa 
Further company coverage:  WL6G.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))